Prosecution Insights
Last updated: November 04, 2026
Application No. 18/878,129

COMPOSITIONS COMPRISING AMINO ACIDS FOR USE IN THE PREVENTION AND/OR TREATMENT OF INTESTINAL DISEASES

Non-Final OA §103§112
Filed
Dec 23, 2024
Priority
Jun 23, 2022 — IT 102022000013354 +1 more
Examiner
CHONG, YONG SOO
Art Unit
1623
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Professional Dietetics S P A
OA Round
1 (Non-Final)
44%
Grant Probability
Moderate
1-2
OA Rounds
2y 0m
Est. Remaining
86%
With Interview

Examiner Intelligence

Grants 44% of resolved cases
44%
Career Allowance Rate
391 granted / 893 resolved
-16.2% vs TC avg
Strong +42% interview lift
Without
With
+41.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 11m
Avg Prosecution
55 currently pending
Career history
961
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
52.7%
+12.7% vs TC avg
§102
21.2%
-18.8% vs TC avg
§112
17.5%
-22.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 893 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Application Claims 1-15 are pending and are examined herein. Claim Rejections - 35 USC § 112 The following is a quotation of the second paragraph of 35 U.S.C. 112(b): The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 2-6, 10-11, 13 are rejected under 35 U.S.C. 112(b) or 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Regarding claims 2-6, 10-11, 13, the phrase "preferably" renders the claim indefinite because it is unclear whether the limitations following the phrases are part of the claimed invention. See MPEP § 2173.05(d). Claims 3-4 are rejected under 35 U.S.C. 112(b) or 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Specifically, claims 3-4 recite the limitation "the branched chain amino acids" in claim 1. There is insufficient antecedent basis for this limitation in the claims. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action: (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made. The factual inquiries set forth in Graham vs John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a). Claims 1-15 are rejected under 35 U.S.C. 103(a) as being obvious over Giorgetti (WO 2019/021137, of record) in view of Guven et al. (WO 2018/191789). The instant claims are directed to a method of treating an intestinal disease by administering leucine, isoleucine, valine, threonine, lysine, citric acid, succinic acid, malic acid, histidine, phenylalanine, methionine, tryptophan, and cysteine. Giorgetti teaches a method of treating or preventing a mitochondrial dysfunction-related disease by administering a composition comprising leucine, isoleucine, valine, threonine, lysine, citric acid, succinic acid, malic acid, histidine, phenylalanine, methionine, tryptophan, and cysteine in the claimed amounts and weight ratios (claims 1-15 and pages 8-10). Further, amino acids preferably excluded by the composition are arginine, serine, proline, and alanine (page 11, lines 9-11). However, Giorgetti fails to disclose the nexus between mitochondrial dysfunction and intestinal diseases. Guven et al. teach that the inflammatory disorders, ulcerative colitis and Crohn’s disease, are associated with mitochondrial dysfunction (paragraph 0018 and claim 21). Therefore, it would have been prima facie obvious to a person of ordinary skill in the art, at the time the claimed invention was made, to have administered the composition comprising the claimed amino acids, as taught by Giorgetti, to a patient suffering from ulcerative colitis and/or Crohn’s disease, as taught by Guven et al. A person of ordinary skill in the art would have been motivated to treat a patient with ulcerative colitis and/or Crohn’s disease by administering a composition comprising the claimed amino acids because Giorgetti teaches that the claimed amino acid composition is useful in the treatment of a mitochondrial dysfunction-related disease. Since ulcerative colitis and Crohn’s disease are known mitochondrial dysfunction-related diseases, one of ordinary skill in the art would have had a reasonable expectation of success in treating these diseases by administering the claimed amino acid composition. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to Yong S. Chong whose telephone number is (571)-272-8513. The examiner can normally be reached Monday to Friday: 9 AM to 5 PM EST. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Adam Milligan, can be reached at (571)-270-7674. The fax phone number for the organization where this application or proceeding is assigned is (571)-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at (866)-217-9197 (toll-free). /Yong S. Chong/Primary Examiner, Art Unit 1623
Read full office action

Prosecution Timeline

Dec 23, 2024
Application Filed
Sep 18, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778957
COMPOSITION FOR ENHANCING INTRA-CELLULAR NITRIC OXIDE GENERATION
3y 5m to grant Granted Nov 03, 2026
Patent 12734158
APPLICATION OF RILUZOLE- AND BORNEOL-CONTAINING COMPOSITION IN PREPARATION OF MEDICATION FOR TREATING CEREBROVASCULAR DISEASES
3y 2m to grant Granted Sep 15, 2026
Patent 12721846
METHODS FOR TREATING BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS IN PATIENTS WITH DEMENTIA
4y 3m to grant Granted Sep 01, 2026
Patent 12714700
METHODS OF TREATING RBP4 RELATED DISEASES WITH TRIAZOLOPYRIDINES
2y 5m to grant Granted Aug 25, 2026
Patent 12691087
METHOD OF ENHANCING GLUCOSE LEVELS IN THE CENTRAL NERVOUS SYSTEM
7y 1m to grant Granted Jul 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
44%
Grant Probability
86%
With Interview (+41.7%)
3y 11m (~2y 0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 893 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month